Cytek Biosciences's gross profit for the
three
months ended in Dec. 2024 was $33.7 Mil. Cytek Biosciences's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $111.1 Mil.
Cytek Biosciences had a gross margin of 58.55% for the quarter that ended in Dec. 2024 => Durable competitive advantage
During the past 6 years, the highestGross Margin % of Cytek Biosciences was 61.86%. The lowest was 49.54%. And the median was 56.20%.
Cytek Biosciences Gross Profit Historical Data
The historical data trend for Cytek Biosciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cytek Biosciences's Gross Profit
For the Medical Devices subindustry, Cytek Biosciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Gross Profit falls into.
Cytek Biosciences Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Cytek Biosciences's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $111.1 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cytek Biosciences had a gross margin of 58.55% for the quarter that ended in Dec. 2024 => Durable competitive advantage
Cytek Biosciences Gross Profit Related Terms
Thank you for viewing the detailed overview of Cytek Biosciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTKB has been successfully added to your 